Olivo Alicia C 4

What Happened

• Alicia C. Olivo, EVP, General Counsel & Business Development of Neogenomics (NEO), was granted two equity awards on March 1, 2026: 147,804 stock options and 89,013 restricted stock units (RSUs). The Form 4 reports these as awards (derivative grants) with a reported acquisition price of $0.00 because they were granted as compensation rather than purchased.
• The stock options are described as premium-price options (the filing says the exercise price was calculated at 110% of a recent closing price — per the filing, using the February 27, 2026 close). The RSUs convert to common shares upon vesting; neither award involved an immediate cash purchase or sale.

Key Details

• Transaction date: March 1, 2026; Filing date: March 3, 2026 (timely).
• Awards: 147,804 stock options; 89,013 restricted stock units. Reported acquisition price: $0.00 (compensation grant).
• Vesting: Both the options and RSUs vest ratably over the first three anniversary dates following the grant (per filing footnotes).
• Exercise price note: Options were granted as premium-price options (exercise price set at 110% of the referenced closing price).
• Shares owned after transaction: Not specified in the summary data provided.
• No sale, purchase, exercise, or tax-withholding transaction reported in this filing — this is a standard compensation grant (Form 4 transaction code A).

Context

• These are compensation awards, not open-market purchases or sales. Because the options are premium-priced (strike above the referenced market price), they have less intrinsic value at grant than at-the-money options and require stock appreciation above the strike to be valuable.
• RSUs vest over time and convert to common shares when vested; such grants are common for executive retention and compensation and do not by themselves indicate insider buying or selling sentiment.